171 related articles for article (PubMed ID: 26041578)
1. Prevention of acute exacerbation of chronic hepatitis B infection in cancer patients receiving chemotherapy in a hepatitis B virus endemic area.
Hsu PI; Lai KH; Cheng JS; Kao SS; Li YR; Sun WC; Chen WC; Lin KH; Shin CA; Chiang PH; Li YD; Ou WT; Chen HC; Yu HC
Hepatology; 2015 Aug; 62(2):387-96. PubMed ID: 26041578
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
3. Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project.
Sampedro B; Hernández-López C; Ferrandiz JR; Illaro A; Fábrega E; Cuadrado A; Iruzubieta P; Menéndez S; Cabezas J; Crespo J
Hepatology; 2014 Jul; 60(1):106-13. PubMed ID: 24585503
[TBL] [Abstract][Full Text] [Related]
4. Updated longitudinal data on acute exacerbation of chronic hepatitis B in patients with breast cancer receiving anthracycline-based adjuvant chemotherapy: therapeutic vs. pre-emptive use of lamivudine.
Sohn BS; Ahn JH; Jung KH; Ahn SH; Son BH; Gong G; Kim SB
Jpn J Clin Oncol; 2011 Sep; 41(9):1059-66. PubMed ID: 21821601
[TBL] [Abstract][Full Text] [Related]
5. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.
Ji D; Cao J; Hong X; Li J; Wang J; Chen F; Wang C; Zou S
Eur J Haematol; 2010 Sep; 85(3):243-50. PubMed ID: 20491883
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
[TBL] [Abstract][Full Text] [Related]
7. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis from an endemic area.
Lv JW; Chen YP; Huang XD; Zhou GQ; Chen L; Li WF; Tang LL; Mao YP; Guo Y; Xu RH; Ma J; Sun Y
Cancer; 2017 Sep; 123(18):3540-3549. PubMed ID: 28493307
[TBL] [Abstract][Full Text] [Related]
9. Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy.
Hwang JP; Suarez-Almazor ME; Cantor SB; Barbo A; Lin HY; Ahmed S; Chavez-MacGregor M; Donato-Santana C; Eng C; Ferrajoli A; Fisch MJ; McLaughlin P; Simon GR; Rondon G; Shpall EJ; Lok AS
Cancer; 2017 Sep; 123(17):3367-3376. PubMed ID: 28518219
[TBL] [Abstract][Full Text] [Related]
10. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
Chen FW; Coyle L; Jones BE; Pattullo V
Liver Int; 2013 Sep; 33(8):1203-10. PubMed ID: 23522150
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.
Lan JL; Chen YM; Hsieh TY; Chen YH; Hsieh CW; Chen DY; Yang SS
Ann Rheum Dis; 2011 Oct; 70(10):1719-25. PubMed ID: 21719446
[TBL] [Abstract][Full Text] [Related]
12. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection.
Kohrt HE; Ouyang DL; Keeffe EB
Clin Liver Dis; 2007 Nov; 11(4):965-91, x. PubMed ID: 17981237
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study.
Seto WK; Chan TS; Hwang YY; Wong DK; Fung J; Liu KS; Gill H; Lam YF; Lie AK; Lai CL; Kwong YL; Yuen MF
J Clin Oncol; 2014 Nov; 32(33):3736-43. PubMed ID: 25287829
[TBL] [Abstract][Full Text] [Related]
14. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.
Yeo W; Ho WM; Hui P; Chan PK; Lam KC; Lee JJ; Johnson PJ
Breast Cancer Res Treat; 2004 Dec; 88(3):209-15. PubMed ID: 15609123
[TBL] [Abstract][Full Text] [Related]
15. Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure.
Sun LJ; Yu JW; Zhao YH; Kang P; Li SC
J Gastroenterol Hepatol; 2010 Mar; 25(3):583-90. PubMed ID: 19968744
[TBL] [Abstract][Full Text] [Related]
16. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.
Yeo W; Chan PK; Ho WM; Zee B; Lam KC; Lei KI; Chan AT; Mok TS; Lee JJ; Leung TW; Zhong S; Johnson PJ
J Clin Oncol; 2004 Mar; 22(5):927-34. PubMed ID: 14990649
[TBL] [Abstract][Full Text] [Related]
17. A single-center, prospective and randomized controlled study: Can the prophylactic use of lamivudine prevent hepatitis B virus reactivation in hepatitis B s-antigen seropositive breast cancer patients during chemotherapy?
Long M; Jia W; Li S; Jin L; Wu J; Rao N; Feng H; Chen K; Deng H; Liu F; Su F; Song E
Breast Cancer Res Treat; 2011 Jun; 127(3):705-12. PubMed ID: 21445574
[TBL] [Abstract][Full Text] [Related]
18. Lamivudine prophylaxis for hepatitis B virus carrier patients with breast cancer during adjuvant chemotherapy.
Lee HJ; Kim DY; Keam B; Lee JH; Han SW; Oh DY; Yoon JH; Kim TY; Kim YJ; Lee KW; Kim JW; Jeong SH; Lee JS; Kim JH; Im SA
Breast Cancer; 2014 Jul; 21(4):387-93. PubMed ID: 23073741
[TBL] [Abstract][Full Text] [Related]
19. Antiviral efficacy analysis of telbivudine concurrent with the first cycle of chemotherapy in HBsAg-positive lymphoma patients.
Li W; Huang L; Guo H; Wei X; Liang Z
J Clin Virol; 2014 Oct; 61(2):199-203. PubMed ID: 25128391
[TBL] [Abstract][Full Text] [Related]
20. Risk of Severe Acute Exacerbation of Chronic HBV Infection Cancer Patients Who Underwent Chemotherapy and Did Not Receive Anti-Viral Prophylaxis.
Shih CA; Chen WC; Yu HC; Cheng JS; Lai KH; Hsu JT; Chen HC; Hsu PI
PLoS One; 2015; 10(8):e0132426. PubMed ID: 26274393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]